June 16, 2014

Allergan issued a statement Monday, reiterating the company's concern for what it calls Valeant Pharmaceuticals’ “unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operational excellence,” the company stated.

April 22, 2014

Allergan on Tuesday confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals to acquire all of the outstanding shares of the company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of Allergan.

October 8, 2013

Lupin Pharmaceuticals announced today that it has launched its generic gatifloxacin ophthalmic solution 0.5%. Lupin had earlier received final approval from the Food and Drug Administration to market a generic version of Allergan's Zymaxid ophthalmic solution, 0.5%, which is indicated for the treatment of bacterial conjunctivitis.

September 16, 2013

The McKesson Patient Relationship Solutions was recognized for its best-in-class adherence solutions by being named a finalist in the 2013 PM360 Trailblazer Awards for the second consecutive year.

June 25, 2013

Drug makers may be allowed to seek approval for a generic version of an eye drug made by Allergan based on lab tests rather than clinical trials, according to published reports.

September 7, 2012

McKesson Patient Relationship Solutions has been named a finalist in both the 2012 Medical Marketing and Media Awards and the PM360 Trailblazer Awards, McKesson announced Friday.

June 19, 2012

The U.S. Court of Appeals for the Federal Circuit ruled in favor of Watson Pharmaceuticals during patent litigation concerning the drug maker's abbreviated new drug application for an overactive bladder treatment.

April 4, 2012

A court has ruled that patents covering a drug used for overactive bladder are invalid, a company looking to launch a generic version of the drug said.

April 3, 2012

Watson is challenging the patent protection on two eye drugs made by Allergan, the generic drug maker said Tuesday.

May 9, 2011

Cypress Pharmaceuticals has launched a generic version of an eye care drug made by Boehringer Ingelheim and marketed by Allergan, the company said.

March 9, 2011

Allergan reappointed David Pyott as president earlier this week, adding to his role as chairman and CEO. Pyott will succeed Michael Ball, who has accepted the position of CEO at Hospira, a specialty pharmaceutical and medication delivery company, Allergan reported.

March 8, 2011

Generic drug maker Hospira has appointed Mike Ball as CEO, effective March 28, the company said. Ball currently is president of Allergan.

February 8, 2011

Valeant Pharmaceuticals subsidiary Biovail Labs International has licensed Canadian rights to a treatment for acne from Allergan, Valeant said Tuesday.

February 1, 2011

Thanks to technological innovations within mascara, the category has driven sales of eye makeup, and looking forward, mascara formulas that are infused with eyelash-enhancing treatments and packaging that offers greater customization not only will volumize lashes but also sales at retail.


January 31, 2011

Anticipating regulatory approval, MAP Pharmaceuticals and Allergan will collaborate to promote a drug for treating acute migraine to physicians.

November 21, 2010

Drug maker OcuSoft has launched a prescription supplement designed to enhance botulinum toxin injections, the...

November 11, 2010

The president and CEO of Agensys, a subsidiary of Japanese drug maker Astellas, will retire,...

October 17, 2010

A popular beauty treatment has won approval as a medical treatment as well....

September 26, 2010

Greenstone announced the launch of an authorized generic version of the Alzheimer’s disease drug Aricept...

September 6, 2010

Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a...

August 31, 2010

Allergan's optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the...

August 1, 2010

The Food and Drug Administration has approved a treatment for muscle spasms and twitches....

March 2, 2010

Bristol-Myers Squibb is buying most of the rights to an investigational pain drug for $40...

January 20, 2010

An investigational drug for treating dry eye didn’t work as well as its developers hoped,...